These Fas DNR-engineered TCR-T or CAR-T cells showed improved persistent anti-tumor activity against established solid and hematologic malignancies.380 Other strategies involve the systemic administration of Fas-Fc or anti-FasL to neutralize FasL. This evidence concerns the gene FAS and neoplasm.